⌘+K

Pulse Explore Communities Researchers Journals

Browser extensionInstagram

Home Communities Explore

August 14, 2024Onco Zine - The International Oncology Network

Europe Approves First Immunotherapy plus PARP Inhibitor Combination in Endometrial Cancer

View at Publisher

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

The European Commission has approved durvalumab (Imfinzi®; AstraZeneca)* and olaparib (Lynparza®; AstraZeneca)**, the first immunotherapy and PARP inhibitor combination, for the treatment for certain patients with primary advanced or recurrent endometrial cancer.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Peter Hofland (2024) studied this question.

synapsesocial.com/papers/68e5c521b6db64358755b642 https://doi.org/10.14229/onco.2024.08.14.001

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1619 Durvalumab plus carboplatin/paclitaxel followed by durvalumab ± olaparib as a first-line treatment for newly diagnosed advanced or recurrent endometrial cancer: results from the phase III DUO-E/GOG-3041/ENGOT-EN10 Trial2024 · 1 citations
2Combination of olaparib, durvalumab and fulvestrant in patients with advanced ER+/HER2- breast cancer and selected genomic alterations: results of the DOLAF trial2025 · 4 citations
394TiP DUOLife: Prospective non-interventional study to generate real-world-data on effectiveness and safety of first-line chemotherapy plus durvalumab followed by maintenance durvalumab or durvalumab + olaparib in endometrial cancer – Study designOriginal Research · 2026
4A Phase II Trial of Olaparib Plus Pembrolizumab in Patients with Recurrent Copy-Number High/p53-Abnormal Endometrial CancerEarly-Phase Clinical Trial · 2026 · 3 citations
5Cost-effectiveness of durvalumab with or without Olaparib as a first-line treatment for dMMR type of advanced/recurrent endometrial cancer2025 · 1 citations
6Phase 3 Clinical Trials Evaluating Poly(ADP-Ribose) Polymerase Inhibition Plus Immunotherapy for First-Line Treatment of Advanced Ovarian Cancer2025 · 2 citations
7FDA Approval Summary: Pembrolizumab plus Lenvatinib for Endometrial Carcinoma, a Collaborative International Review under Project OrbisHuman Clinical Trial · 2020 · 101 citations
8Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer2023 · 825 citations
9Rebuilding Pharmacy Benefit Integrity: The Role of Transparent Rebate Administration in OncologyOnco Zine - The International Oncology Network · 2025
10The Missing Link in Oncology’s Value-Based Future: Lifestyle SupportOnco Zine - The International Oncology Network · 2025

More from Onco Zine - The International Oncology Network